Thomas McCauley, PhD, on Proof-of Concept With In Vivo Epigenomic Editing
The chief scientific officer at Omega Therapeutics discussed how the MYCHELANGEO-1 trial may validate the company’s OEC platform.
Thomas McCauley, PhD, on Continuing Evaluations on OTX-2002 for MYC-Expressing Cancers
The chief scientific officer at Omega Therapeutics discussed milestones Omega Therapeutics is looking forward to in the next year.
Thomas McCauley, PhD, on Potential Advantages of Epigenetic Therapy Over Small Molecule, Gene Therapy
The chief scientific officer at Omega Therapeutics discussed the issues with other modes of therapies that OEC therapy may address.
Thomas McCauley, PhD, on the Potential of Epigenetics for Therapy Development
The chief scientific officer at Omega Therapeutics discussed the importance of understanding more about and researching epigenetics.
Thomas McCauley, PhD, on Treating Solid Tumors With Epigenomic Controllers
The chief scientific officer at Omega Therapeutics discussed positive preclinical data presented at ASCO 2023.